Preliminary Report - ID Mapping
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
covid:unpublished [2020/05/01 16:34] biogridadmin |
covid:unpublished [2021/04/24 15:17] (current) biogridadmin |
||
|---|---|---|---|
| Line 5: | Line 5: | ||
| **WARNING** - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. | **WARNING** - Please treat these papers with caution as they are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. | ||
| - | + | ||
| - | ^ Custom ID ^ DOI ^ Author ^ Dataset ^ | + | ^ Custom ID ^ DOI ^ AUTHOR ^ DATASET ^ |
| - | | **888800000001** | **[[https://doi.org/10.1101/2020.03.22.002386|10.1101/2020.03.22.002386]]** | Gordon DE (2020) | **[[https://thebiogrid.org/220839/publication|A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing]]** | | + | |
| | **888800000002** | **[[https://doi.org/10.1101/2020.03.29.20041962|10.1101/2020.03.29.20041962]]** | Gao T (2020) | **[[https://thebiogrid.org/221112/publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** | | | **888800000002** | **[[https://doi.org/10.1101/2020.03.29.20041962|10.1101/2020.03.29.20041962]]** | Gao T (2020) | **[[https://thebiogrid.org/221112/publication|Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation]]** | | ||
| - | | **888800000003** | **[[https://doi.org/10.1101/2020.02.16.951723|10.1101/2020.02.16.951723]]** | Xie L (2020) | **[[https://thebiogrid.org/221178/publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** | | + | | **888800000003** | **[[https://doi.org/10.1101/2020.02.16.951723|10.1101/2020.02.16.951723]]** | Sun C (2020) | **[[https://thebiogrid.org/221178/publication|SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development]]** | |
| - | | **888800000004** | **[[https://doi.org/10.1101/2020.03.16.994236|10.1101/2020.03.16.994236]]** | Procko E (2020) | **[[https://thebiogrid.org/221182/publication|The sequence of human ACE2 is suboptimal for binding the S spike protein of SARS coronavirus 2]]** | | + | |
| | **888800000005** | **[[https://doi.org/10.1101/2020.03.14.988345|10.1101/2020.03.14.988345]]** | Wang K (2020) | **[[https://thebiogrid.org/221183/publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** | | | **888800000005** | **[[https://doi.org/10.1101/2020.03.14.988345|10.1101/2020.03.14.988345]]** | Wang K (2020) | **[[https://thebiogrid.org/221183/publication|SARS-CoV-2 invades host cells via a novel route: CD147-spike protein]]** | | ||
| | **888800000006** | **[[https://doi.org/10.1101/2020.02.17.951848|10.1101/2020.02.17.951848]]** | Zhou Q (2020) | **[[https://thebiogrid.org/221185/publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]** | | | **888800000006** | **[[https://doi.org/10.1101/2020.02.17.951848|10.1101/2020.02.17.951848]]** | Zhou Q (2020) | **[[https://thebiogrid.org/221185/publication|Structure of dimeric full-length human ACE2 in complex with B0AT1]]** | | ||
| + | | **888800000007** | **[[https://doi.org/10.1101/2020.02.26.964882|10.1101/2020.02.26.964882]]** | Jin Z (2020) | **[[https://thebiogrid.org/221186/publication|Structure of Mpro from COVID-19 virus and discovery of its inhibitors [DEPRECATED PUBLICATION]]]** | | ||
| | **888800000008** | **[[https://doi.org/10.1101/2020.03.29.013490|10.1101/2020.03.29.013490]]** | Wang C (2020) | **[[https://thebiogrid.org/221195/publication|Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2]]** | | | **888800000008** | **[[https://doi.org/10.1101/2020.03.29.013490|10.1101/2020.03.29.013490]]** | Wang C (2020) | **[[https://thebiogrid.org/221195/publication|Lectin-like Intestinal Defensin Inhibits 2019-nCoV Spike binding to ACE2]]** | | ||
| | **888800000009** | **[[https://doi.org/10.1101/2020.03.25.996348|10.1101/2020.03.25.996348]]** | Dai W (2020) | **[[https://thebiogrid.org/221196/publication|Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease]]** | | | **888800000009** | **[[https://doi.org/10.1101/2020.03.25.996348|10.1101/2020.03.25.996348]]** | Dai W (2020) | **[[https://thebiogrid.org/221196/publication|Structure-Based Design, Synthesis and Biological Evaluation of Peptidomimetic Aldehydes as a Novel Series of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease]]** | | ||
| | **888800000010** | **[[https://doi.org/10.1101/2020.03.15.992883|10.1101/2020.03.15.992883]]** | Joyce MG (2020) | **[[https://thebiogrid.org/221197/publication|A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein]]** | | | **888800000010** | **[[https://doi.org/10.1101/2020.03.15.992883|10.1101/2020.03.15.992883]]** | Joyce MG (2020) | **[[https://thebiogrid.org/221197/publication|A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein]]** | | ||
| | **888800000011** | **[[https://doi.org/10.1101/2020.03.16.993386|10.1101/2020.03.16.993386]]** | Gao Y (2020) | **[[https://thebiogrid.org/221198/publication|Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target]]** | | | **888800000011** | **[[https://doi.org/10.1101/2020.03.16.993386|10.1101/2020.03.16.993386]]** | Gao Y (2020) | **[[https://thebiogrid.org/221198/publication|Structure of RNA-dependent RNA polymerase from 2019-nCoV, a major antiviral drug target]]** | | ||
| - | | **888800000012** | **[[https://doi.org/10.1101/2020.03.31.019216|10.1101/2020.03.31.019216]]** | Liang Q (2020) | **[[https://thebiogrid.org/221199/publication|Virus-host interactome and proteomic survey of PMBCs from COVID-19 patients reveal potential virulence factors influencing SARS-CoV-2 pathogenesis]]** | | ||
| | **888800000013** | **[[https://doi.org/10.1101/2020.04.15.042085|10.1101/2020.04.15.042085]]** | Bestle D (2020) | **[[https://thebiogrid.org/221402/publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]** | | | **888800000013** | **[[https://doi.org/10.1101/2020.04.15.042085|10.1101/2020.04.15.042085]]** | Bestle D (2020) | **[[https://thebiogrid.org/221402/publication|TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS-CoV-2 in human airway epithelial cells and provide promising drug targets]]** | | ||
| - | | **888800000014** | **[[https://doi.org/10.1101/2020.04.09.033233|10.1101/2020.04.09.033233]]** | Jin Z (2020) | **[[https://thebiogrid.org/221403/publication|Structural basis for the inhibition of COVID-19 virus main protease by carmofur, an antineoplastic drug]]** | | + | | **888800000018** | **[[https://doi.org/10.1101/2020.04.19.049643|10.1101/2020.04.19.049643]]** | Zeng X (2020) | **[[https://thebiogrid.org/221566/publication|Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy]]** | |
| - | | **888800000015** | **[[https://doi.org/10.1101/2020.04.08.032763|10.1101/2020.04.08.032763]]** | Yin W (2020) | **[[https://thebiogrid.org/221404/publication|Structural Basis for the Inhibition of the RNA-Dependent RNA Polymerase from SARS-CoV-2 by Remdesivir]]** | | + | | **888800000020** | **[[https://doi.org/10.1101/2020.04.22.046565|10.1101/2020.04.22.046565]]** | Liu Y (2020) | **[[https://thebiogrid.org/221568/publication|Functional and Genetic Analysis of Viral Receptor ACE2 Orthologs Reveals Broad Potential Host Range of SARS-CoV-2]]** | |
| - | | **888800000016** | **[[https://doi.org/10.1101/2020.04.14.042010|10.1101/2020.04.14.042010]]** | Chi X (2020) | **[[https://thebiogrid.org/221405/publication|Humanized Single Domain Antibodies Neutralize SARS-CoV-2 by Targeting Spike Receptor Binding Domain]]** | | + | | **888800000021** | **[[https://doi.org/10.1101/2020.04.21.053017|10.1101/2020.04.21.053017]]** | Walker A (2020) | **[[https://thebiogrid.org/221569/publication|Enisamium is a small molecule inhibitor of the influenza A virus and SARS-CoV-2 RNA polymerases]]** | |
| + | | **888800000022** | **[[https://doi.org/10.1101/2020.04.17.047498|10.1101/2020.04.17.047498]]** | Rosas Lemus M (2020) | **[[https://thebiogrid.org/221570/publication|The crystal structure of nsp10-nsp16 heterodimer from SARS CoV-2in complex with S-adenosylmethionine]]** | | ||
| + | | **888800000025** | **[[https://doi.org/10.1101/2020.04.29.068890|10.1101/2020.04.29.068890]]** | Rut W (2020) | **[[https://thebiogrid.org/221777/publication|Activity profiling of SARS-CoV-2-PLpro protease provides structural framework for anti-COVID-19 drug design]]** | | ||
| + | | **888800000029** | **[[https://doi.org/10.1101/2020.05.02.20086876|10.1101/2020.05.02.20086876]]** | Zhang D (2020) | **[[https://thebiogrid.org/221831/publication|Ultra-fast and onsite interrogation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in environmental specimens via surface enhanced Raman scattering (SERS)]]** | | ||
| + | | **888800000031** | **[[https://doi.org/10.1101/2020.05.06.079830|10.1101/2020.05.06.079830]]** | Zha L (2020) | **[[https://thebiogrid.org/221833/publication|Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles]]** | | ||
| + | | **888800000032** | **[[https://doi.org/10.1101/2020.05.02.043554|10.1101/2020.05.02.043554]]** | Gunther S (2020) | **[[https://thebiogrid.org/221835/publication|Catalytic cleavage of HEAT and subsequent covalent binding of the tetralone moiety by the SARS-CoV-2 main protease]]** | | ||
| + | | **888800000034** | **[[https://doi.org/10.1101/2020.05.03.074914|10.1101/2020.05.03.074914]]** | Liu X (2020) | **[[https://thebiogrid.org/221959/publication|Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-CoV-2 Infection]]** | | ||
| + | | **888800000035** | **[[https://doi.org/10.1101/2020.05.21.109157|10.1101/2020.05.21.109157]]** | Lui I (2020) | **[[https://thebiogrid.org/222215/publication|Trimeric SARS-CoV-2 Spike interacts with dimeric ACE2 with limited intra-Spike avidity]]** | | ||
| + | | **888800000036** | **[[https://doi.org/10.1101/2020.05.21.107870|10.1101/2020.05.21.107870]]** | Partridge LJ (2020) | **[[https://thebiogrid.org/222216/publication|Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line]]** | | ||
| + | | **888800000037** | **[[https://doi.org/10.1101/2020.05.13.092478|10.1101/2020.05.13.092478]]** | Chiodo F (2020) | **[[https://thebiogrid.org/222217/publication|Novel ACE2-Independent Carbohydrate-Binding of SARS-CoV-2 Spike Protein to Host Lectins and Lung Microbiota]]** | | ||
| + | | **888800000038** | **[[https://doi.org/10.1101/2020.05.12.091298|10.1101/2020.05.12.091298]]** | Seydoux E (2020) | **[[https://thebiogrid.org/222218/publication|Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual]]** | | ||
| + | | **888800000040** | **[[https://doi.org/10.1101/2020.05.12.092171|10.1101/2020.05.12.092171]]** | Zhou X (2020) | **[[https://thebiogrid.org/222220/publication|Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformation]]** | | ||
| + | | **888800000041** | **[[https://doi.org/10.1101/2020.06.17.156455|10.1101/2020.06.17.156455]]** | Stukalov A (2020) | **[[https://thebiogrid.org/222410/publication|Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV]]** | | ||
| + | | **888800000042** | **[[https://doi.org/10.1101/2020.06.05.135921|10.1101/2020.06.05.135921]]** | Bertoglio F (2020) | **[[https://thebiogrid.org/222602/publication|SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface]]** | | ||
| + | | **888800000043** | **[[https://doi.org/10.1101/2020.06.05.135699|10.1101/2020.06.05.135699]]** | Moustaqil M (2020) | **[[https://thebiogrid.org/222603/publication|SARS-CoV-2 proteases cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species and the search for reservoir hosts.]]** | | ||
| + | | **888800000046** | **[[https://doi.org/10.1101/2020.06.17.158121|10.1101/2020.06.17.158121]]** | Cubuk J (2020) | **[[https://thebiogrid.org/222654/publication|The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA]]** | | ||
| + | | **888800000050** | **[[https://doi.org/10.1101/2020.06.07.138677|10.1101/2020.06.07.138677]]** | Luan X (2020) | **[[https://thebiogrid.org/222705/publication|Structure Basis for Inhibition of SARS-CoV-2 by the Feline Drug GC376]]** | | ||
| + | | **888800000052** | **[[https://doi.org/10.1101/2020.06.06.137513|10.1101/2020.06.06.137513]]** | Lou Y (2020) | **[[https://thebiogrid.org/222707/publication|Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries]]** | | ||
| + | | **888800000054** | **[[https://doi.org/10.1101/2020.06.16.155812|10.1101/2020.06.16.155812]]** | Li J (2020) | **[[https://thebiogrid.org/222709/publication|Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin]]** | | ||
| + | | **888800000056** | **[[https://doi.org/10.1101/2020.06.16.154708|10.1101/2020.06.16.154708]]** | Hanson QM (2020) | **[[https://thebiogrid.org/223039/publication|Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay]]** | | ||
| + | | **888800000063** | **[[https://doi.org/10.1101/2020.07.31.230730|10.1101/2020.07.31.230730]]** | Cao W (2020) | **[[https://thebiogrid.org/223096/publication|Biomechanical Characterization of SARS-CoV-2 Spike RBD and Human ACE2 Protein-Protein Interaction]]** | | ||
| + | | **888800000064** | **[[https://doi.org/10.1101/2020.07.24.219857|10.1101/2020.07.24.219857]]** | Esparza TJ (2020) | **[[https://thebiogrid.org/223097/publication|High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme]]** | | ||
| + | | **888800000065** | **[[https://doi.org/10.1101/2020.07.25.221036|10.1101/2020.07.25.221036]]** | Shilts J (2020) | **[[https://thebiogrid.org/223098/publication|No evidence for basigin/CD147 as a direct SARS-CoV-2 spike binding receptor]]** | | ||
| + | | **888800000066** | **[[https://doi.org/10.1101/2020.07.13.201517|10.1101/2020.07.13.201517]]** | Davies JP (2020) | **[[https://thebiogrid.org/223099/publication|Comparative multiplexed interactomics of SARS-CoV-2 and homologous coronavirus non-structural proteins identifies unique and shared host-cell dependencies]]** | | ||
| + | | **888800000067** | **[[https://doi.org/10.1101/2020.07.31.229781|10.1101/2020.07.31.229781]]** | Alitongbieke G (2020) | **[[https://thebiogrid.org/223100/publication|Study on beta-Chitosan against the binding of SARS-CoV-2S-RBD/ACE2]]** | | ||
| + | | **888800000069** | **[[https://doi.org/10.1101/2020.07.27.224089|10.1101/2020.07.27.224089]]** | Beasley MD (2020) | **[[https://thebiogrid.org/223102/publication|Antibodies that potently inhibit or enhance SARS-CoV-2 spike protein-ACE2 interaction isolated from synthetic single-chain antibody libraries]]** | | ||
| + | | **888800000070** | **[[https://doi.org/10.1101/2020.07.29.227462|10.1101/2020.07.29.227462]]** | Gao C (2020) | **[[https://thebiogrid.org/223103/publication|SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors]]** | | ||
| + | | **888800000071** | **[[https://doi.org/10.1101/2020.07.26.222026|10.1101/2020.07.26.222026]]** | Zheng Y (2020) | **[[https://thebiogrid.org/223104/publication|Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Membrane (M) Protein Inhibits Type I and III Interferon Production by Targeting RIG-I/MDA-5 Signaling]]** | | ||
| + | | **888800000072** | **[[https://doi.org/10.1101/2020.07.30.229187|10.1101/2020.07.30.229187]]** | Shi W (2020) | **[[https://thebiogrid.org/223105/publication|A dynamic regulatory interface on SARS-CoV-2 RNA polymerase]]** | | ||
| + | | **888800000075** | **[[https://doi.org/10.1101/2020.07.15.204404|10.1101/2020.07.15.204404]]** | Schmidt N (2020) | **[[https://thebiogrid.org/223108/publication|A direct RNA-protein interaction atlas of the SARS-CoV-2 RNA in infected human cells]]** | | ||
| + | | **888800000076** | **[[https://doi.org/10.1101/2020.08.03.234914|10.1101/2020.08.03.234914]]** | Cao L (2020) | **[[https://thebiogrid.org/223109/publication|De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. [DEPRECATED]]]** | | ||
| + | | **888800000078** | **[[https://doi.org/10.1101/2020.07.17.208959|10.1101/2020.07.17.208959]]** | Fu Z (2020) | **[[https://thebiogrid.org/223111/publication|Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules]]** | | ||
| + | | **888800000079** | **[[https://doi.org/10.1101/2020.07.31.231282|10.1101/2020.07.31.231282]]** | Tee KL (2020) | **[[https://thebiogrid.org/223112/publication|Purification of recombinant SARS-CoV-2 spike, its receptor binding domain, and CR3022 mAb for serological assay]]** | | ||
| + | | **888800000080** | **[[https://doi.org/10.1101/2020.07.25.220806|10.1101/2020.07.25.220806]]** | Temerozo JR (2020) | **[[https://thebiogrid.org/223113/publication|The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells and decrease the production of proinflammatory cytokines in infected cells.]]** | | ||
| + | | **888800000081** | **[[https://doi.org/10.1101/2020.08.03.234559|10.1101/2020.08.03.234559]]** | Addetia A (2020) | **[[https://thebiogrid.org/223399/publication|SARS-CoV-2 ORF6 disrupts nucleocytoplasmic transport through interactions with Rae1 and Nup98]]** | | ||
| + | | **888800000082** | **[[https://doi.org/10.1101/2020.08.28.272955|10.1101/2020.08.28.272955]]** | Laurent E (2020) | **[[https://thebiogrid.org/223400/publication|Global BioID-based SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms]]** | | ||
| + | | **888800000083** | **[[https://doi.org/10.1101/2020.08.20.259770|10.1101/2020.08.20.259770]]** | Lapointe CP (2020) | **[[https://thebiogrid.org/223461/publication|Dynamic competition between SARS-CoV-2 NSP1 and mRNA on the human ribosome inhibits translation initiation]]** | | ||
| + | | **888800000084** | **[[https://doi.org/10.1101/2020.08.16.252973|10.1101/2020.08.16.252973]]** | Han L (2020) | **[[https://thebiogrid.org/223462/publication|SARS-CoV-2 ORF9b Antagonizes Type I and III Interferons by Targeting Multiple Components of RIG-I/MDA-5-MAVS, TLR3-TRIF, and cGAS-STING Signaling Pathways]]** | | ||
| + | | **888800000085** | **[[https://doi.org/10.1101/2020.08.06.238915|10.1101/2020.08.06.238915]]** | Watson A (2020) | **[[https://thebiogrid.org/223463/publication|Peptide Antidotes to SARS-CoV-2 (COVID-19)]]** | | ||
| + | | **888800000086** | **[[https://doi.org/10.1101/2020.08.12.247767|10.1101/2020.08.12.247767]]** | Yang Z (2020) | **[[https://thebiogrid.org/223464/publication|Suppression of MDA5-mediated antiviral immune responses by NSP8 of SARS-CoV-2]]** | | ||
| + | | **888800000087** | **[[https://doi.org/10.1101/2020.08.12.246389|10.1101/2020.08.12.246389]]** | Risner K (2020) | **[[https://thebiogrid.org/223465/publication|Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture]]** | | ||
| + | | **888800000088** | **[[https://doi.org/10.1101/2020.08.08.238469|10.1101/2020.08.08.238469]]** | Schoof M (2020) | **[[https://thebiogrid.org/223466/publication|An ultra-high affinity synthetic nanobody blocks SARS-CoV-2 infection by locking Spike into an inactive conformation]]** | | ||
| + | | **888800000089** | **[[https://doi.org/10.1101/2020.08.14.250258|10.1101/2020.08.14.250258]]** | Chen Y (2020) | **[[https://thebiogrid.org/223467/publication|Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 main protease by tafenoquine in vitro]]** | | ||
| + | | **888800000090** | **[[https://doi.org/10.1101/2020.08.09.242917|10.1101/2020.08.09.242917]]** | Thepaut M (2020) | **[[https://thebiogrid.org/223468/publication|DC/L-SIGN recognition of spike glycoprotein promotes SARS-CoV-2 trans-infection and can be inhibited by a glycomimetic antagonist]]** | | ||
| + | | **888800000093** | **[[https://doi.org/10.1101/2020.08.18.256776|10.1101/2020.08.18.256776]]** | Andres AD (2020) | **[[https://thebiogrid.org/223471/publication|SARS-CoV-2 ORF9c Is a Membrane-Associated Protein that Suppresses Antiviral Responses in Cells]]** | | ||
| + | | **888800000094** | **[[https://doi.org/10.1101/2020.08.13.249177|10.1101/2020.08.13.249177]]** | Carrique L (2020) | **[[https://thebiogrid.org/223473/publication|The SARS-CoV-2 Spike harbours a lipid binding pocket which modulates stability of the prefusion trimer]]** | | ||
| + | | **888800000095** | **[[https://doi.org/10.1101/2020.08.13.248211|10.1101/2020.08.13.248211]]** | Baddock HT (2020) | **[[https://thebiogrid.org/223474/publication|Characterisation of the SARS-CoV-2 ExoN (nsp14ExoN-nsp10) complex: implications for its role in viral genome stability and inhibitor identification]]** | | ||
| + | | **888800000096** | **[[https://doi.org/10.1101/2020.08.10.244525|10.1101/2020.08.10.244525]]** | Malla TN (2020) | **[[https://thebiogrid.org/223475/publication|Ebselen Reacts with SARS Coronavirus-2 Main Protease Crystals]]** | | ||
| + | | **888800000097** | **[[https://doi.org/10.1101/2020.08.11.244863|10.1101/2020.08.11.244863]]** | Pillon MC (2020) | **[[https://thebiogrid.org/223476/publication|Cryo-EM Structures of the SARS-CoV-2 Endoribonuclease Nsp15]]** | | ||
| + | | **888800000098** | **[[https://doi.org/10.1101/2020.08.12.247338|10.1101/2020.08.12.247338]]** | Wang C (2020) | **[[https://thebiogrid.org/223477/publication|Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection]]** | | ||
| + | | **888800000099** | **[[https://doi.org/10.1101/2020.08.14.251421|10.1101/2020.08.14.251421]]** | Wilamowski M (2020) | **[[https://thebiogrid.org/223478/publication|Methylation of RNA Cap in SARS-CoV-2 captured by serial crystallography]]** | | ||
| + | | **888800000100** | **[[https://doi.org/10.1101/2020.08.13.248872|10.1101/2020.08.13.248872]]** | Wei C (2020) | **[[https://thebiogrid.org/223479/publication|SARS-CoV-2 manipulates the SR-B1-mediated HDL uptake pathway for its entry]]** | | ||
| + | | **888800000101** | **[[https://doi.org/10.1101/2020.08.14.251207|10.1101/2020.08.14.251207]]** | Heaton BE (2020) | **[[https://thebiogrid.org/223480/publication|SRSF protein kinases 1 and 2 are essential host factors for human coronaviruses including SARS-CoV-2]]** | | ||
| + | | **888800000103** | **[[https://doi.org/10.1101/2020.08.09.242867|10.1101/2020.08.09.242867]]** | Gai J (2020) | **[[https://thebiogrid.org/223482/publication|A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential]]** | | ||
| + | | **888800000104** | **[[https://doi.org/10.1101/2020.09.03.282103|10.1101/2020.09.03.282103]]** | Samavarchi-Tehrani P (2020) | **[[https://thebiogrid.org/223517/publication|A SARS-CoV-2 - host proximity interactome]]** | | ||
| + | | **888800000105** | **[[https://doi.org/10.1101/2020.09.09.287508|10.1101/2020.09.09.287508]]** | Gu Y (2020) | **[[https://thebiogrid.org/223561/publication|Interaction network of SARS-CoV-2 with host receptome through spike protein]]** | | ||
| + | | **888800000106** | **[[https://doi.org/10.1101/2020.08.29.273441|10.1101/2020.08.29.273441]]** | Bojadzic D (2020) | **[[https://thebiogrid.org/223562/publication|Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19]]** | | ||
| + | | **888800000107** | **[[https://doi.org/10.1101/2020.09.04.282558|10.1101/2020.09.04.282558]]** | Bouwman KM (2020) | **[[https://thebiogrid.org/223563/publication|Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins]]** | | ||
| + | | **888800000108** | **[[https://doi.org/10.1101/2020.08.28.271601|10.1101/2020.08.28.271601]]** | Dash P (2020) | **[[https://thebiogrid.org/223564/publication|Sequence analysis of Indian SARS-CoV-2 isolates shows a stronger interaction of mutated receptor binding domain with ACE2 receptor]]** | | ||
| + | | **888800000109** | **[[https://doi.org/10.1101/2020.08.28.269175|10.1101/2020.08.28.269175]]** | St-Germain JR (2020) | **[[https://thebiogrid.org/223565/publication|A SARS-CoV-2 BioID-based virus-host membrane protein interactome and virus peptide compendium: new proteomics resources for COVID-19 research]]** | | ||
| + | | **888800000111** | **[[https://doi.org/10.1101/2020.09.04.280081|10.1101/2020.09.04.280081]]** | Qiang X (2020) | **[[https://thebiogrid.org/223567/publication|Monoclonal Antibodies Capable of Binding SARS-CoV-2 Spike Protein Receptor Binding Motif Specifically Prevent GM-CSF Induction.]]** | | ||
| + | | **888800000112** | **[[https://doi.org/10.1101/2020.09.09.287987|10.1101/2020.09.09.287987]]** | Durdagi S (2020) | **[[https://thebiogrid.org/223568/publication|Near-Physiological-Temperature Serial Femtosecond X-ray Crystallography Reveals Novel Conformations of SARS-CoV-2 Main Protease Active Site for Improved Drug Repurposing]]** | | ||
| + | | **888800000113** | **[[https://doi.org/10.1101/2020.09.01.277954|10.1101/2020.09.01.277954]]** | Bartolome A (2020) | **[[https://thebiogrid.org/223569/publication|Angiotensin converting enzyme 2 is a novel target of the secretase complex]]** | | ||
| + | | **888800000115** | **[[https://doi.org/10.1101/2020.09.09.289488|10.1101/2020.09.09.289488]]** | Kotani N (2020) | **[[https://thebiogrid.org/223571/publication|Candidate screening of host cell membrane proteins involved in SARS-CoV-2 entry]]** | | ||
| + | | **888800000116** | **[[https://doi.org/10.1101/2020.08.27.270637|10.1101/2020.08.27.270637]]** | Flower TG (2020) | **[[https://thebiogrid.org/223572/publication|Structure of SARS-CoV-2 ORF8, a rapidly evolving coronavirus protein implicated in immune evasion]]** | | ||
| + | | **888800000117** | **[[https://doi.org/10.1101/2020.09.21.307439|10.1101/2020.09.21.307439]]** | Wang X (2020) | **[[https://thebiogrid.org/223769/publication|Bat and pangolin coronavirus spike glycoprotein structures provide insights into SARS-CoV-2 evolution]]** | | ||
| + | | **888800000118** | **[[https://doi.org/10.1101/2020.09.14.295956|10.1101/2020.09.14.295956]]** | Lin C (2020) | **[[https://thebiogrid.org/223770/publication|Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction]]** | | ||
| + | | **888800000119** | **[[https://doi.org/10.1101/2020.09.16.297366|10.1101/2020.09.16.297366]]** | Sagar S (2020) | **[[https://thebiogrid.org/223771/publication|Bromelain Inhibits SARS-CoV-2 Infection in VeroE6 Cells]]** | | ||
| + | | **888800000120** | **[[https://doi.org/10.1101/2020.09.18.301952|10.1101/2020.09.18.301952]]** | Xiao T (2020) | **[[https://thebiogrid.org/223772/publication|A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro]]** | | ||
| + | | **888800000121** | **[[https://doi.org/10.1101/2020.09.16.297945|10.1101/2020.09.16.297945]]** | Meyer B (2020) | **[[https://thebiogrid.org/223773/publication|Characterisation of protease activity during SARS-CoV-2 infection identifies novel viral cleavage sites and cellular targets for drug repurposing]]** | | ||
| + | | **888800000122** | **[[https://doi.org/10.1101/2020.09.22.308338|10.1101/2020.09.22.308338]]** | Wagner TR (2020) | **[[https://thebiogrid.org/223774/publication|NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response]]** | | ||
| + | | **888800000123** | **[[https://doi.org/10.1101/2020.09.20.297242|10.1101/2020.09.20.297242]]** | Ren W (2020) | **[[https://thebiogrid.org/223775/publication|Comparative analysis reveals the species-specific genetic determinants of ACE2 required for SARS-CoV-2 entry]]** | | ||
| + | | **888800000124** | **[[https://doi.org/10.1101/2020.09.13.295691|10.1101/2020.09.13.295691]]** | Olaleye OA (2020) | **[[https://thebiogrid.org/223776/publication|Ambroxol Hydrochloride Inhibits the Interaction between Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein's Receptor Binding Domain and Recombinant Human ACE2.]]** | | ||
| + | | **888800000125** | **[[https://doi.org/10.1101/2020.09.16.300319|10.1101/2020.09.16.300319]]** | Tada T (2020) | **[[https://thebiogrid.org/223777/publication|A soluble ACE2 microbody protein fused to a single immunoglobulin Fc domain is a potent inhibitor of SARS-CoV-2 infection in cell culture]]** | | ||
| + | | **888800000126** | **[[https://doi.org/10.1101/2020.09.16.299891|10.1101/2020.09.16.299891]]** | Higuchi Y (2020) | **[[https://thebiogrid.org/223778/publication|High affinity modified ACE2 receptors prevent SARS-CoV-2 infection]]** | | ||
| + | | **888800000127** | **[[https://doi.org/10.1101/2020.09.16.20190694|10.1101/2020.09.16.20190694]]** | Ichimura T (2020) | **[[https://thebiogrid.org/223779/publication|KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney]]** | | ||
| + | | **888800000128** | **[[https://doi.org/10.1101/2020.11.04.361154|10.1101/2020.11.04.361154]]** | de Vries (2020) | **[[https://thebiogrid.org/225841/publication|Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets]]** | | ||
| + | | **888800000129** | **[[https://doi.org/10.1101/2020.10.13.336800|10.1101/2020.10.13.336800]]** | Yan R (2020) | **[[https://thebiogrid.org/225985/publication|Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies]]** | | ||
| + | | **888800000130** | **[[https://doi.org/10.1101/2020.09.27.315796|10.1101/2020.09.27.315796]]** | Bauer MS (2020) | **[[https://thebiogrid.org/225986/publication|A Tethered Ligand Assay to Probe the SARS-CoV-2 ACE2 Interaction under Constant Force]]** | | ||
| + | | **888800000131** | **[[https://doi.org/10.1101/2020.10.06.328112|10.1101/2020.10.06.328112]]** | Lutomski CA (2020) | **[[https://thebiogrid.org/225987/publication|Autoproteolytic Products of the SARS-CoV-2 Nucleocapsid Protein are Primed for Antibody Evasion and Virus Proliferation]]** | | ||
| + | | **888800000132** | **[[https://doi.org/10.1101/2020.10.31.363473|10.1101/2020.10.31.363473]]** | Stevens BR (2020) | **[[https://thebiogrid.org/225988/publication|TMPRSS2 and ADAM17 interactions with ACE2 complexed with SARS-CoV-2 and B0AT1 putatively in intestine, cardiomyocytes, and kidney]]** | | ||
| + | | **888800000133** | **[[https://doi.org/10.1101/2020.10.23.350348|10.1101/2020.10.23.350348]]** | Tang X (2020) | **[[https://thebiogrid.org/225989/publication|Transferrin receptor is another receptor for SARS-CoV-2 entry]]** | | ||
| + | | **888800000134** | **[[https://doi.org/10.1101/2020.11.04.361576|10.1101/2020.11.04.361576]]** | Li W (2020) | **[[https://thebiogrid.org/225990/publication|Human Identical Sequences of SARS-CoV-2 Promote Clinical Progression of COVID-19 by Upregulating Hyaluronan via NamiRNA-Enhancer Network]]** | | ||
| + | | **888800000135** | **[[https://doi.org/10.1101/2020.10.29.352450|10.1101/2020.10.29.352450]]** | Bakovic A (2020) | **[[https://thebiogrid.org/225991/publication|Brilacidin, a COVID-19 Drug Candidate, Exhibits Potent In Vitro Antiviral Activity Against SARS-CoV-2]]** | | ||
| + | | **888800000136** | **[[https://doi.org/10.1101/2020.10.26.356048|10.1101/2020.10.26.356048]]** | Liu G (2020) | **[[https://thebiogrid.org/225992/publication|ISG15-dependent Activation of the RNA Sensor MDA5 and its Antagonism by the SARS-CoV-2 papain-like protease]]** | | ||
| + | | **888800000137** | **[[https://doi.org/10.1101/2020.10.16.342097|10.1101/2020.10.16.342097]]** | Gao X (2020) | **[[https://thebiogrid.org/225993/publication|Duple extinguishment of COVID-19: single compound synergized inhibition of SARS-CoV-2 replication and direct suppression of inflammatory cytokines in vitro/vivo]]** | | ||
| + | | **888800000138** | **[[https://doi.org/10.1101/2020.10.13.337584|10.1101/2020.10.13.337584]]** | Roy A (2020) | **[[https://thebiogrid.org/225994/publication|ACIS, A Novel KepTide(tm), Binds to ACE-2 Receptor and Inhibits the Infection of SARS-CoV2 Virus in vitro in Primate Kidney Cells: Therapeutic Implications for COVID-19]]** | | ||
| + | | **888800000139** | **[[https://doi.org/10.1101/2020.10.30.361873|10.1101/2020.10.30.361873]]** | Andring JT (2020) | **[[https://thebiogrid.org/225995/publication|Amino acid transporter B0AT1 influence on ADAM17 interactions with SARS-CoV-2 receptor ACE2 putatively expressed in intestine, kidney, and cardiomyocytes]]** | | ||
| + | | **888800000140** | **[[https://doi.org/10.1101/2020.10.23.347534|10.1101/2020.10.23.347534]]** | Mellott D (2020) | **[[https://thebiogrid.org/225996/publication|A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells]]** | | ||
| + | | **888800000141** | **[[https://doi.org/10.1101/2020.10.06.327742|10.1101/2020.10.06.327742]]** | Kliche J (2020) | **[[https://thebiogrid.org/225997/publication|Cytoplasmic short linear motifs in ACE2 and integrin beta3 link SARS-CoV-2 host cell receptors to endocytosis and autophagy]]** | | ||
| + | | **888800000142** | **[[https://doi.org/10.1101/2020.10.18.344622|10.1101/2020.10.18.344622]]** | Chan KK (2020) | **[[https://thebiogrid.org/225998/publication|An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants]]** | | ||
| + | | **888800000143** | **[[https://doi.org/10.1101/2020.11.01.363788|10.1101/2020.11.01.363788]]** | Sun J (2020) | **[[https://thebiogrid.org/225999/publication|Discovery of five HIV nucleoside analog reverse-transcriptase inhibitors (NRTIs) as potent inhibitors against the RNA-dependent RNA polymerase (RdRp) of SARS-CoV and 2019-nCoV]]** | | ||
| + | | **888800000144** | **[[https://doi.org/10.1101/2020.10.30.362335|10.1101/2020.10.30.362335]]** | Hu Y (2020) | **[[https://thebiogrid.org/226000/publication|Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture]]** | | ||
| + | | **888800000145** | **[[https://doi.org/10.1101/2020.10.11.335299|10.1101/2020.10.11.335299]]** | Gobeil S (2020) | **[[https://thebiogrid.org/226001/publication|D614G mutation alters SARS-CoV-2 spike conformational dynamics and protease cleavage susceptibility at the S1/S2 junction]]** | | ||
| + | | **888800000146** | **[[https://doi.org/10.1101/2020.10.06.327445|10.1101/2020.10.06.327445]]** | Flynn RA (2020) | **[[https://thebiogrid.org/226002/publication|Systematic discovery and functional interrogation of SARS-CoV-2 viral RNA-host protein interactions during infection]]** | | ||
| + | | **888800000147** | **[[https://doi.org/10.1101/2020.09.24.312553|10.1101/2020.09.24.312553]]** | Li Y (2020) | **[[https://thebiogrid.org/226003/publication|SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial derived cells and cardiomyocytes]]** | | ||
| + | | **888800000148** | **[[https://doi.org/10.1101/2020.10.22.351569|10.1101/2020.10.22.351569]]** | Nguyen HT (2020) | **[[https://thebiogrid.org/226004/publication|Spike glycoprotein and host cell determinants of SARS-CoV-2 entry and cytopathic effects]]** | | ||
| + | | **888800000149** | **[[https://doi.org/10.1101/2020.10.22.351056|10.1101/2020.10.22.351056]]** | Bojadzic D (2020) | **[[https://thebiogrid.org/226005/publication|Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2]]** | | ||
| + | | **888800000150** | **[[https://doi.org/10.1101/2020.10.08.20209114|10.1101/2020.10.08.20209114]]** | Wu F (2020) | **[[https://thebiogrid.org/226006/publication|Antibody-dependent enhancement (ADE) of SARS-CoV-2 infection in recovered COVID-19 patients: studies based on cellular and structural biology analysis]]** | | ||
| + | | **888800000151** | **[[https://doi.org/10.1101/2020.09.30.317818|10.1101/2020.09.30.317818]]** | Hsu AC-Y (2020) | **[[https://thebiogrid.org/226007/publication|SARS-CoV-2 Spike protein promotes hyper-inflammatory response that can be ameliorated by Spike-antagonistic peptide and FDA-approved ER stress and MAP kinase inhibitors in vitro]]** | | ||
| + | | **888800000152** | **[[https://doi.org/10.1101/2020.11.05.369264|10.1101/2020.11.05.369264]]** | Soh WT (2020) | **[[https://thebiogrid.org/226008/publication|The N-terminal domain of spike glycoprotein mediates SARS-CoV-2 infection by associating with L-SIGN and DC-SIGN]]** | | ||
| + | | **888800000153** | **[[https://doi.org/10.1101/2020.12.02.408153|10.1101/2020.12.02.408153]]** | Roth A (2020) | **[[https://thebiogrid.org/226406/publication|LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro]]** | | ||
| + | | **888800000154** | **[[https://doi.org/10.1101/2020.11.24.20237628|10.1101/2020.11.24.20237628]]** | Al Ahmad M (2020) | **[[https://thebiogrid.org/226407/publication|Development of an Optical Assay to Detect SARS-CoV-2 Spike Protein Binding Interactions with ACE2 and Disruption of these Interactions Using Electric Current]]** | | ||
| + | | **888800000155** | **[[https://doi.org/10.1101/2020.12.06.413443|10.1101/2020.12.06.413443]]** | Svilenov HL (2020) | **[[https://thebiogrid.org/226408/publication|Efficient inhibition of SARS-CoV-2 strains by a novel ACE2-IgG4-Fc fusion protein with a stabilized hinge region]]** | | ||
| + | | **888800000156** | **[[https://doi.org/10.1101/2020.12.01.406116|10.1101/2020.12.01.406116]]** | Tito A (2020) | **[[https://thebiogrid.org/226409/publication|A pomegranate peel extract as inhibitor of SARS-CoV-2 Spike binding to human ACE2 (in vitro): a promising source of novel antiviral drugs]]** | | ||
| + | | **888800000157** | **[[https://doi.org/10.1101/2020.11.24.393629|10.1101/2020.11.24.393629]]** | Wang X (2020) | **[[https://thebiogrid.org/226410/publication|Double Lock of a Potent Human Monoclonal Antibody against SARS-CoV-2]]** | | ||
| + | | **888800000158** | **[[https://doi.org/10.1101/2020.12.03.409441|10.1101/2020.12.03.409441]]** | Rossetti GG (2020) | **[[https://thebiogrid.org/226411/publication|Identification of low micromolar SARS-CoV-2 Mpro inhibitors from hits identified by in silico screens]]** | | ||
| + | | **888800000159** | **[[https://doi.org/10.1101/2020.11.11.378018|10.1101/2020.11.11.378018]]** | Eberle RJ (2020) | **[[https://thebiogrid.org/226412/publication|The repurposed drugs suramin and quinacrine inhibit cooperatively in vitro SARS-CoV-2 3CLpro]]** | | ||
| + | | **888800000160** | **[[https://doi.org/10.1101/2020.11.12.378422|10.1101/2020.11.12.378422]]** | Guenther S (2020) | **[[https://thebiogrid.org/226413/publication|Inhibition of SARS-CoV-2 main protease by allosteric drug-binding]]** | | ||
| + | | **888800000161** | **[[https://doi.org/10.1101/2020.12.06.412759|10.1101/2020.12.06.412759]]** | Calistri A (2020) | **[[https://thebiogrid.org/226414/publication|The new generation hDHODH inhibitor MEDS433 hinders the in vitro replication of SARS-CoV-2]]** | | ||
| + | | **888800000162** | **[[https://doi.org/10.1101/2020.12.03.409318|10.1101/2020.12.03.409318]]** | Bertoglio F (2020) | **[[https://thebiogrid.org/226415/publication|A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to known RBD mutations]]** | | ||
| + | | **888800000163** | **[[https://doi.org/10.1101/2020.11.06.368191|10.1101/2020.11.06.368191]]** | Kraus A (2020) | **[[https://thebiogrid.org/226416/publication|A zebrafish model for COVID-19 recapitulates olfactory and cardiovascular pathophysiologies caused by SARS-CoV-2]]** | | ||
| + | | **888800000164** | **[[https://doi.org/10.1101/2020.12.23.424149|10.1101/2020.12.23.424149]]** | Noske G (2020) | **[[https://thebiogrid.org/226619/publication|A Crystallographic Snapshot of SARS-CoV-2 Main Protease Maturation Process]]** | | ||
| + | | **888800000165** | **[[https://doi.org/10.1101/2020.12.18.423427|10.1101/2020.12.18.423427]]** | Zhao Y (2020) | **[[https://thebiogrid.org/226620/publication|SARS-CoV-2 spike protein interacts with and activates TLR4]]** | | ||
| + | | **888800000166** | **[[https://doi.org/10.1101/2020.12.19.423537|10.1101/2020.12.19.423537]]** | Kitamura N (2020) | **[[https://thebiogrid.org/226621/publication|An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity]]** | | ||
| + | | **888800000167** | **[[https://doi.org/10.1101/2020.12.23.424171|10.1101/2020.12.23.424171]]** | Schmitz A (2020) | **[[https://thebiogrid.org/226622/publication|A SARS-CoV-2 spike binding DNA aptamer that inhibits pseudovirus infection in vitro by an RBD independent mechanism]]** | | ||
| + | | **888800000168** | **[[https://doi.org/10.1101/2020.12.31.424961|10.1101/2020.12.31.424961]]** | Chen Z (2021) | **[[https://thebiogrid.org/226623/publication|Comprehensive analysis of the host-virus interactome of SARS-CoV-2]]** | | ||
| + | | **888800000169** | **[[https://doi.org/10.1101/2020.12.21.423721|10.1101/2020.12.21.423721]]** | Avolio E (2020) | **[[https://thebiogrid.org/226624/publication|The SARS-CoV-2 spike protein disrupts the cooperative function of human cardiac pericytes - endothelial cells through CD147 receptor-mediated signalling: a potential non-infective mechanism of COVID-19 microvascular disease]]** | | ||
| + | | **888800000170** | **[[https://doi.org/10.1101/2020.12.19.423584|10.1101/2020.12.19.423584]]** | Garcia-Dorival I (2020) | **[[https://thebiogrid.org/226625/publication|Identification of NPC1 as a novel SARS-CoV-2 intracellular target]]** | | ||
| + | | **888800000171** | **[[https://doi.org/10.1101/2020.12.26.424423|10.1101/2020.12.26.424423]]** | Durdagi S (2020) | **[[https://thebiogrid.org/226626/publication|The neutralization effect of Montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies]]** | | ||
| + | | **888800000172** | **[[https://doi.org/10.1101/2020.12.18.423415|10.1101/2020.12.18.423415]]** | Madan T (2020) | **[[https://thebiogrid.org/226627/publication|A recombinant fragment of Human surfactant protein D binds Spike protein and inhibits infectivity and replication of SARS-CoV-2 in clinical samples]]** | | ||
| + | | **888800000173** | **[[https://doi.org/10.1101/2020.12.29.424698|10.1101/2020.12.29.424698]]** | Yang X (2020) | **[[https://thebiogrid.org/226628/publication|An Ultrasensitive Biosensor for Quantifying the Interaction of SARS-CoV-2 and Its Receptor ACE2 in Cells and in vitro]]** | | ||
| + | | **888800000174** | **[[https://doi.org/10.1101/2020.12.20.422820|10.1101/2020.12.20.422820]]** | Fiedler S (2020) | **[[https://thebiogrid.org/226629/publication|In vitro measurements of protein-protein interactions show that antibody affinity governs the inhibition of SARS-CoV-2 spike/ACE2 binding in convalescent serum]]** | | ||
| + | | **888800000175** | **[[https://doi.org/10.1101/2020.12.22.422708|10.1101/2020.12.22.422708]]** | Shepley-McTaggart A (2020) | **[[https://thebiogrid.org/226630/publication|SARS-CoV-2 Envelope (E) Protein Interacts with PDZ-Domain-2 of Host Tight Junction Protein ZO1]]** | | ||
| + | | **888800000176** | **[[https://doi.org/10.1101/2020.12.18.423418|10.1101/2020.12.18.423418]]** | Hsieh M-H (2020) | **[[https://thebiogrid.org/226631/publication|Human Surfactant Protein D Binds S1 and Receptor Binding Domain of Spike protein and acts as an entry inhibitor of SARS-CoV-2 Pseudotyped viral particles in vitro]]** | | ||
| + | | **888800000177** | **[[https://doi.org/10.1101/2020.12.16.422677|10.1101/2020.12.16.422677]]** | Kuzikov M (2020) | **[[https://thebiogrid.org/226632/publication|Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen]]** | | ||
| + | | **888800000178** | **[[https://doi.org/10.1101/2020.12.30.424801|10.1101/2020.12.30.424801]]** | Woo HG (2020) | **[[https://thebiogrid.org/226633/publication|Pharmacophore-based peptide biologics neutralize SARS-CoV-2 S1 and deter S1-ACE2 interaction in vitro]]** | | ||
| + | | **888800000179** | **[[https://doi.org/10.1101/2020.12.26.424422|10.1101/2020.12.26.424422]]** | Xu W (2020) | **[[https://thebiogrid.org/226634/publication|Extensive High-Order Complexes within SARS-CoV-2 Proteome Revealed by Compartmentalization-Aided Interaction Screening]]** | | ||
| + | | **888800000180** | **[[https://doi.org/10.1101/2020.12.09.417741|10.1101/2020.12.09.417741]]** | Armstrong L (2020) | **[[https://thebiogrid.org/226635/publication|Characterization of protease activity of Nsp3 from SARS-CoV-2 and its in vitro inhibition by nanobodies]]** | | ||
| + | | **888800000181** | **[[https://doi.org/10.1101/2020.12.29.424682|10.1101/2020.12.29.424682]]** | Kuznetsov A (2020) | **[[https://thebiogrid.org/226636/publication|ACE2 peptide fragment interacts with several sites on the SARS-CoV-2 spike protein S1]]** | | ||
| + | | **888800000182** | **[[https://doi.org/10.1101/2021.01.21.427657|10.1101/2021.01.21.427657]]** | Choi R (2021) | **[[https://thebiogrid.org/226858/publication|High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.]]** | | ||
| + | | **888800000183** | **[[https://doi.org/10.1101/2021.01.12.426388|10.1101/2021.01.12.426388]]** | Kneller DW (2021) | **[[https://thebiogrid.org/226859/publication|Inhibitor Binding Modulates Protonation States in the Active Site of SARS-CoV-2 Main Protease]]** | | ||
| + | | **888800000184** | **[[https://doi.org/10.1101/2021.01.17.427000|10.1101/2021.01.17.427000]]** | Wan Y (2021) | **[[https://thebiogrid.org/226860/publication|Comprehensive mapping of SARS-CoV-2 interactions in vivo reveals functional virus-host interactions]]** | | ||
| + | | **888800000185** | **[[https://doi.org/10.1101/2021.01.19.427194|10.1101/2021.01.19.427194]]** | Tian R (2021) | **[[https://thebiogrid.org/226861/publication|BRD2 inhibition blocks SARS-CoV-2 infection in vitro by reducing transcription of the host cell receptor ACE2]]** | | ||
| + | | **888800000186** | **[[https://doi.org/10.1101/2021.01.11.426269|10.1101/2021.01.11.426269]]** | Zhu X (2021) | **[[https://thebiogrid.org/226862/publication|Cryo-EM Structure of the N501Y SARS-CoV-2 Spike Protein in Complex with a Potent Neutralizing Antibody]]** | | ||
| + | | **888800000187** | **[[https://doi.org/10.1101/2021.01.05.425478|10.1101/2021.01.05.425478]]** | Kamle S (2021) | **[[https://thebiogrid.org/226863/publication|Chitinase 3-like-1 is a Therapeutic Target That Mediates the Effects of Aging in COVID-19]]** | | ||
| + | | **888800000188** | **[[https://doi.org/10.1101/2021.01.14.426695|10.1101/2021.01.14.426695]]** | Carnell GW (2021) | **[[https://thebiogrid.org/226864/publication|SARS-CoV-2 spike protein arrested in the closed state induces potent neutralizing responses]]** | | ||
| + | | **888800000189** | **[[https://doi.org/10.1101/2021.01.13.21249429|10.1101/2021.01.13.21249429]]** | Hultstrom M (2021) | **[[https://thebiogrid.org/226865/publication|Elevated Angiopoietin-2 inhibits thrombomodulin-mediated anticoagulation in critically ill COVID-19 patients]]** | | ||
| + | | **888800000190** | **[[https://doi.org/10.1101/2021.01.19.427324|10.1101/2021.01.19.427324]]** | Suryadevara N (2021) | **[[https://thebiogrid.org/226866/publication|Neutralizing and protective human monoclonal antibodies recognizing the N-terminaldomain of the SARS-CoV-2 spike protein]]** | | ||
| + | | **888800000191** | **[[https://doi.org/10.1101/2021.01.11.426218|10.1101/2021.01.11.426218]]** | Rapp M (2021) | **[[https://thebiogrid.org/226867/publication|Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class]]** | | ||
| + | | **888800000192** | **[[https://doi.org/10.1101/2021.01.07.425745|10.1101/2021.01.07.425745]]** | Saramago M (2021) | **[[https://thebiogrid.org/226868/publication|New targets for drug design: Importance of nsp14/nsp10 complex formation for the 3'-5' exoribonucleolytic activity on SARS-CoV-2]]** | | ||
| + | | **888800000193** | **[[https://doi.org/10.1101/2021.01.12.426042|10.1101/2021.01.12.426042]]** | Siniavin AE (2021) | **[[https://thebiogrid.org/226869/publication|Snake venom phospholipases A2 possess a strong virucidal activity against SARS-CoV-2 in vitro and block the cell fusion mediated by spike glycoprotein interaction with the ACE2 receptor]]** | | ||
| + | | **888800000194** | **[[https://doi.org/10.1101/2021.01.07.425806|10.1101/2021.01.07.425806]]** | Bell BN (2021) | **[[https://thebiogrid.org/226870/publication|Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naive human antibody library]]** | | ||
| + | | **888800000195** | **[[https://doi.org/10.1101/2021.01.20.427368|10.1101/2021.01.20.427368]]** | Carlos AJ (2021) | **[[https://thebiogrid.org/226871/publication|GRP78 binds SARS-CoV-2 Spike protein and ACE2 and GRP78 depleting antibody blocks viral entry and infection in vitro]]** | | ||
| + | | **888800000196** | **[[https://doi.org/10.1101/2021.01.05.425516|10.1101/2021.01.05.425516]]** | Verma R (2021) | **[[https://thebiogrid.org/226872/publication|RNA-protein interaction analysis of SARS-CoV-2 5'- and 3'-untranslated regions identifies an antiviral role of lysosome-associated membrane protein-2]]** | | ||
| + | | **888800000197** | **[[https://doi.org/10.1101/2021.01.29.428890|10.1101/2021.01.29.428890]]** | Berndt AJ (2021) | **[[https://thebiogrid.org/227046/publication|Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii]]** | | ||
| + | | **888800000198** | **[[https://doi.org/10.1101/2021.01.29.428834|10.1101/2021.01.29.428834]]** | Bayarri-Olmos R (2021) | **[[https://thebiogrid.org/227047/publication|The SARS-CoV-2 Y453F mink variant displays a striking increase in ACE-2 affinity but does not challenge antibody neutralization]]** | | ||
| + | | **888800000199** | **[[https://doi.org/10.1101/2021.02.03.429601|10.1101/2021.02.03.429601]]** | Prahlad J (2021) | **[[https://thebiogrid.org/227048/publication|Bacterial expression and purification of functional recombinant SARS-CoV-2 spike receptor binding domain]]** | | ||
| + | | **888800000200** | **[[https://doi.org/10.1101/2021.02.03.429625|10.1101/2021.02.03.429625]]** | Khalili Yazdi A (2021) | **[[https://thebiogrid.org/227049/publication|A high-throughput radioactivity-based assay for screening SARS-CoV-2 nsp10-nsp16 complex]]** | | ||
| + | | **888800000201** | **[[https://doi.org/10.1101/2021.02.01.429176|10.1101/2021.02.01.429176]]** | Caillet-Saguy C (2021) | **[[https://thebiogrid.org/227050/publication|Host PDZ-containing proteins targeted by SARS-Cov-2]]** | | ||
| + | | **888800000202** | **[[https://doi.org/10.1101/2021.02.11.430866|10.1101/2021.02.11.430866]]** | Liu H (2021) | **[[https://thebiogrid.org/227051/publication|A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection]]** | | ||
| + | | **888800000203** | **[[https://doi.org/10.1101/2021.02.02.429311|10.1101/2021.02.02.429311]]** | Ma H (2021) | **[[https://thebiogrid.org/227052/publication|Potent in vitro Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain]]** | | ||
| + | | **888800000204** | **[[https://doi.org/10.1101/2021.02.19.424337|10.1101/2021.02.19.424337]]** | Devkota K (2021) | **[[https://thebiogrid.org/227053/publication|Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors]]** | | ||
| + | | **888800000205** | **[[https://doi.org/10.1101/2021.02.13.431008|10.1101/2021.02.13.431008]]** | Shen Z (2021) | **[[https://thebiogrid.org/227054/publication|Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures]]** | | ||
| + | | **888800000206** | **[[https://doi.org/10.1101/2021.02.17.431617|10.1101/2021.02.17.431617]]** | Bollavaram K (2021) | **[[https://thebiogrid.org/227055/publication|Multiple Sites on SARS-CoV-2 Spike Protein are Susceptible to Proteolysis by Cathepsins B, K, L, S, and V]]** | | ||
| + | | **888800000207** | **[[https://doi.org/10.1101/2021.01.31.429023|10.1101/2021.01.31.429023]]** | Minasov G (2021) | **[[https://thebiogrid.org/227056/publication|Mn2+ coordinates Cap-0-RNA to align substrates for efficient 2'-O-methyl transfer by SARS-CoV-2 nsp16]]** | | ||
| + | | **888800000208** | **[[https://doi.org/10.1101/2021.02.03.429355|10.1101/2021.02.03.429355]]** | Graham C (2021) | **[[https://thebiogrid.org/227057/publication|Impact of the B.1.1.7 variant on neutralizing monoclonal antibodies recognizing diverse epitopes on SARS-CoV-2 Spike]]** | | ||
| + | | **888800000209** | **[[https://doi.org/10.1101/2021.02.09.430451|10.1101/2021.02.09.430451]]** | Spelios MG (2021) | **[[https://thebiogrid.org/227058/publication|A novel antibody against the furin cleavage site of SARS-CoV-2 spike protein: effects on proteolytic cleavage and ACE2 binding]]** | | ||
| + | | **888800000210** | **[[https://doi.org/10.1101/2021.02.02.428884|10.1101/2021.02.02.428884]]** | Zhang G (2021) | **[[https://thebiogrid.org/227059/publication|The basis of a more contagious 501Y.V1 variant of SARS-COV-2]]** | | ||
| + | | **888800000211** | **[[https://doi.org/10.1101/2021.02.16.431021|10.1101/2021.02.16.431021]]** | Arutyunova E (2021) | **[[https://thebiogrid.org/227060/publication|N-Terminal finger stabilizes the reversible feline drug GC376 in SARS-CoV-2 Mpro]]** | | ||
| + | | **888800000212** | **[[https://doi.org/10.1101/2021.02.07.429299|10.1101/2021.02.07.429299]]** | Gu C (2021) | **[[https://thebiogrid.org/227061/publication|A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques]]** | | ||
| + | | **888800000213** | **[[https://doi.org/10.1101/2021.02.04.429751|10.1101/2021.02.04.429751]]** | Slavin M (2021) | **[[https://thebiogrid.org/227062/publication|Targeted in situ cross-linking mass spectrometry and integrative modeling reveal the architectures of Nsp1, Nsp2, and Nucleocapsid proteins from SARS-CoV-2]]** | | ||
| + | | **888800000214** | **[[https://doi.org/10.1101/2021.02.08.430344|10.1101/2021.02.08.430344]]** | Zhao H (2021) | **[[https://thebiogrid.org/227063/publication|Energetic and structural features of SARS-CoV-2 N-protein co-assemblies with nucleic acids]]** | | ||
| + | | **888800000215** | **[[https://doi.org/10.1101/2021.02.14.431117|10.1101/2021.02.14.431117]]** | Tian F (2021) | **[[https://thebiogrid.org/227064/publication|Mutation N501Y in RBD of Spike Protein Strengthens the Interaction between COVID-19 and its Receptor ACE2]]** | | ||
| + | | **888800000216** | **[[https://doi.org/10.1101/2021.02.17.431755|10.1101/2021.02.17.431755]]** | Zhao Y (2021) | **[[https://thebiogrid.org/227065/publication|SARS-CoV-2 nucleocapsid protein dually regulates innate immune responses]]** | | ||